Focus:
Immunology
-
8 June 2020 storefronts
Solvias
Solvias is a world leader in contract research and development (R&D), providing the pharmaceutical, biotech and medical device industries with integrated analytical services and solutions for safer products.
-
20 March 2020 storefronts
Inke
Inke is an exclusively held subsidiary of Neuraxpharm, which focuses on the production and development of high-quality active pharmaceutical ingredients (APIs) with compound synthesis processes for central nervous system (CNS)...
-
26 February 2020 projects
Astellas Pharma’s New Manufacturing Facility, Toyama
Astellas Pharma unveiled its plans to construct an active pharmaceutical ingredient (API) manufacturing facility in Toyama, Japan, in January 2020.
-
25 February 2020 News
STADA agrees to buy 15 consumer healthcare brands from GSK
Germany-based STADA has agreed to buy a portfolio of 15 consumer healthcare brands from GlaxoSmithKline (GSK) in European countries, including Germany, France, Poland, Italy, Russia, Spain and Switzerland.
-
20 February 2020 Comment
Bi-specific antibodies as keys to augment the effects of immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) have provided an unprecedented duration of response and disease-free survival outcomes in cancer therapy, a feat that has enabled their integration as the backbone treatment-of-choice in...
-
17 February 2020 Analysis
Twitter round-up: Prof Peter Hotez’s tweet on New Zealand’s measles outbreak top tweet in Q4 2019
Pharmaceutical Technology lists ten of the top tweets on infectious diseases in Q4 2019, based on data from GlobalData’s Influencer Platform. The top tweets were chosen from influencers as tracked...
-
17 February 2020 News
Takeda’s SC Entyvio meets primary endpoint in Crohn’s Disease
At the European Crohn’s and Colitis Organization (ECCO) congress in Vienna, Austria, Takeda announced the subcutaneous (SC) formulation of Entyvio (vedolizumab) met its primary endpoint in Crohn’s Disease.
-
22 January 2020 News
Horizon Therapeutics gets FDA approval for thyroid eye disease drug
Irish pharmaceutical company Horizon Therapeutics has received the US Food and Drug Administration (FDA) approval for Tepezza (teprotumumab-trbw) to treat thyroid eye disease (TED).
-
8 January 2020 Analysis
No more siloes: linking rheumatology and CVD with Abcentra
Although there are evidence-based links between CVD and inflammatory conditions, and associated strong risk factors, they are often ignored when treating patients with either type of condition. Abcentra former CEO...
-
23 December 2019 Comment
FDA grants breakthrough therapy designation to ImmunityBio’s novel IL-15 superagonist N-803
The IL-15 receptor plays a very important role in the immune system by affecting the maintenance, function, and development of natural killer and T- cells.